Clinical Trial Update: ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on ADI-PEG 20 with radiotherapy and temozolomide for glioblastoma, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Polaris Group | Conditions: Glioblastoma Multiforme (GBM) | Phase 2 | Status: ACTIVE_NOT_RECRUITING